SEC Form 4 · accession 0001209191-15-009408
Decoy Therapeutics Inc. · DCOY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Peter Barton Hutt
Director
Period of report
Feb 3, 2015
Accepted (ET)
Feb 4, 2015 · 4:15 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001615219
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 3, 2015 | C | 11,675 | $0.00 | A | 11,675 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series A Preferred StockF1,F2,F3 | $0.00 | Feb 3, 2015 | C | 50,000 | A | — | — | Common Stock | 50,000 | 0 | D |
Explanation of responses
- F1The shares automatically converted on a 4.2825-for-1 basis into shares of the Issuer's Common Stock upon the closing of a Qualified Public Offering (as defined in the Amended and Restated Certificate of Incorporation).
- F2N/A.
- F3The shares have no expiration date.